Schedule 13G ownership disclosure
Novus Therapeutics, Inc.
Security class unavailable · CUSIP: 67011N105
Event date: 2017-05-09
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 8.9000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-17-177838
- Form type
- SC 13G
- Filer
- Eledon Pharmaceuticals, Inc.
- CIK
- CIK 1404281
- Filed
- May 22, 2017
- Reporting period
- May 09, 2017
- Description
- Schedule 13G beneficial ownership